User profiles for Eric D. Shah
 | Eric Dinesh Shah, MD, MBAUniversity of Michigan Verified email at umich.edu Cited by 1849 |
Abnormal breath testing in IBS: a meta-analysis
ED Shah, RJ Basseri, K Chong, M Pimentel - Digestive diseases and …, 2010 - Springer
Background Recent evidence suggests a role for enteric bacteria in the development of
symptoms in subjects with irritable bowel syndrome (IBS). The concept was initially based on the …
symptoms in subjects with irritable bowel syndrome (IBS). The concept was initially based on the …
Digestive manifestations in patients hospitalized with coronavirus disease 2019
Background & Aims The prevalence and significance of digestive manifestations in
coronavirus disease 2019 (COVID-19) remain uncertain. We aimed to assess the prevalence, …
coronavirus disease 2019 (COVID-19) remain uncertain. We aimed to assess the prevalence, …
Efficacy and tolerability of guanylate cyclase-C agonists for irritable bowel syndrome with constipation and chronic idiopathic constipation: a systematic review and …
… : Eric Shah and Philip Schoenfeld conducted the study and collected and interpreted data.
Eric Shah drafted the manuscript and both authors edited the manuscript. Eric Shah and …
Eric Shah drafted the manuscript and both authors edited the manuscript. Eric Shah and …
Risk for overall infection with anti-TNF and anti-integrin agents used in IBD: a systematic review and meta-analysis
ED Shah, JP Farida, CA Siegel, K Chong… - Inflammatory bowel …, 2017 - academic.oup.com
Background The overall risk for infection with contemporary biological agents in treating
Crohn's disease (CD) and ulcerative colitis (UC) has not been systematically assessed. …
Crohn's disease (CD) and ulcerative colitis (UC) has not been systematically assessed. …
American Gastroenterological Association-American College of Gastroenterology clinical practice guideline: Pharmacological management of chronic idiopathic …
Introduction Chronic idiopathic constipation (CIC) is a common disorder associated with
significant impairment in quality of life. This clinical practice guideline, jointly developed by the …
significant impairment in quality of life. This clinical practice guideline, jointly developed by the …
Systematic review: hepatosplenic T‐cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse …
ED Shah, ES Coburn, A Nayyar, KJ Lee… - Alimentary …, 2020 - Wiley Online Library
Background Hepatosplenic T‐cell lymphoma (HSTCL) is a rare, poorly treatable malignancy
associated with therapy for IBD. Current knowledge of HSTCL risk in IBD comes from an era …
associated with therapy for IBD. Current knowledge of HSTCL risk in IBD comes from an era …
Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder with a
multifactorial pathophysiology. The gut microbiota differs between patients with IBS and healthy …
multifactorial pathophysiology. The gut microbiota differs between patients with IBS and healthy …
The time is now: a guide to sustainable telemedicine during COVID-19 and beyond
ED Shah, ST Amann, JJ Karlitz - Official journal of the American …, 2020 - journals.lww.com
We outline important considerations on telemedicine, including licensing requirements,
malpractice coverage, choice of platform, and reimbursement. This study not only serves to …
malpractice coverage, choice of platform, and reimbursement. This study not only serves to …
Comparing costs and outcomes of treatments for irritable bowel syndrome with diarrhea: cost-benefit analysis
Background Irritable bowel syndrome (IBS) is one of the most expensive gastroenterological
conditions and is an ideal target for developing a value-based care model. We assessed …
conditions and is an ideal target for developing a value-based care model. We assessed …
[PDF][PDF] ALIMENTARY TRACT
BACKGROUND & AIMS: The prevalence and significance of digestive manifestations in
coronavirus disease 2019 (COVID-19) remain uncertain. We aimed to assess the prevalence, …
coronavirus disease 2019 (COVID-19) remain uncertain. We aimed to assess the prevalence, …
